Trials / Active Not Recruiting
Active Not RecruitingNCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Detailed description
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide | Post Transplant Cyclophosphamide |
| DRUG | Anti-Thymocyte globulin (rabbit) | Anti-Thymocyte Globulin (rabbit, Thymoglobulin) |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2024-05-18
- Completion
- 2026-02-07
- First posted
- 2019-12-18
- Last updated
- 2025-05-11
Locations
9 sites across 2 countries: Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04202835. Inclusion in this directory is not an endorsement.